ALX Oncology
在场
高管
查看带有其 22 名主要高管的组织结构图
ALX Oncology 搜索最多的简介
高管在ALX Oncology变化
- Jason Lettmann 曾任 Director, 现升职为 Chief Executive Officer (新闻发布的2023九月7号).
创建提醒
跟踪 ALX Oncology 的高管变动
生物技术
ALX Oncology 拥有 2,282 家竞争者，其中包括 Lonza (瑞士)、Eurofins (卢森堡) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Endeavor BioMedicines 刚刚宣布为 132 筹款数百万美元。 (公布2024四月25号).
- Metsera 刚刚宣布为 290 筹款数百万美元。 (公布2024四月23号).
- Histogen has filed for bankruptcy protection (公布2024四月19号).
生物技术 行业的其他推荐联系人
消息
ALX Oncology 的最新新闻稿
- ALX Oncology’s Evorpacept Receives Fast Track Designation from FDA as First-Line Treatment for Head and Neck Squamous Cell Carcinoma – ALX Oncology
- ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Acute Myeloid Leukemia – ALX Oncology
- ALX Oncology Announces Evorpacept Clinical Program Updates – ALX Oncology
- ALX Oncology to Participate in the Jefferies 2022 Healthcare Conference – ALX Oncology
- ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights – ALX Oncology
- ALX Oncology Announces Initiation of Investigator-Sponsored Trial of Evorpacept (ALX148) in Patients with Indolent and Aggressive Non-Hodgkin Lymphoma – ALX Oncology
- ALX Oncology Announces Upcoming Virtual Investor Conference Participation – ALX Oncology
- ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights – ALX Oncology
- ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) and Chemotherapy for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma – ALX Oncology
- ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or Gastroesophageal Junction Cancer – ALX Oncology
- View more press releases Close
关于 ALX Oncology 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 Jason Lettmann 
